APA (7th ed.) Citation

Abdel-Razeq, H., Cottu, P. H., Ring, A., Laurentiis, M. D., Lu, J., Azim, H. A., . . . Menon, L. (2018). 328PRibociclib (RIBO) + letrozole (LET) in premenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) with no prior endocrine therapy (ET) for ABC: Preliminary subgroup results from the phase IIIb CompLEEment-1 trial. Annals of Oncology, 29, N.PAG. https://doi.org/10.1093/annonc/mdy272.318

Chicago Style (17th ed.) Citation

Abdel-Razeq, H., et al. "328PRibociclib (RIBO) + Letrozole (LET) in Premenopausal Patients (pts) with Hormone Receptor-positive (HR+), Human Epidermal Growth Factor Receptor-2–negative (HER2–) Advanced Breast Cancer (ABC) with No Prior Endocrine Therapy (ET) for ABC: Preliminary Subgroup Results from the Phase IIIb CompLEEment-1 Trial." Annals of Oncology 29 (2018): N.PAG. https://doi.org/10.1093/annonc/mdy272.318.

MLA (9th ed.) Citation

Abdel-Razeq, H., et al. "328PRibociclib (RIBO) + Letrozole (LET) in Premenopausal Patients (pts) with Hormone Receptor-positive (HR+), Human Epidermal Growth Factor Receptor-2–negative (HER2–) Advanced Breast Cancer (ABC) with No Prior Endocrine Therapy (ET) for ABC: Preliminary Subgroup Results from the Phase IIIb CompLEEment-1 Trial." Annals of Oncology, vol. 29, 2018, p. N.PAG, https://doi.org/10.1093/annonc/mdy272.318.